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Purpose: Previous experiments from our laboratory showed that the oral intake of selected guanidino compounds could
block the formation of crystallin-bound advanced ascorbylation products. Here we tested whether these were also active
when applied as eye drops.
Methods: Two month old hSVCT2 transgenic mice (n=10) were treated twice daily with one drop of 0.1% L-arginine,
γ-guanidinobutyric acid (GBA), penicillamine (PA) or N-acetylcysteine (NAC) in one eye and vehicle only in the other
eye. After seven months, lens crystallins were isolated, dialyzed, and proteolytically digested to determine the protein-
bound fluorescence at 335/385 and 370/440 nm excitation/emission and the advanced glycation/ascorbylation endproducts
carboxymethyl-lysine (CML), carboxyethyl-lysine (CEL), glucosepane, glyoxal, and methylglyoxal hydroimidazolones
G-H1 and MG-H1. The topical uptake of L-arginine and NAC was also evaluated in vitro and in vivo in rabbit lens.
Results: In hSVCT2 mice, L-arginine decreased 335/385 and 370/440 nm fluorescence by 40% (p<0.001), CML, CEL,
and glucosepane crystallin crosslinks by 35% (p<0.05), 30% (p<0.05), and 37% (p<0.05), respectively, without affecting
MG-H1 and G-H1. NAC decreased 335/385 nm fluorescence by 50% (p<0.001) but, like PA and GBA, had no effect on
other modifications. L-Arginine uptake into rabbit eyes treated topically reached identical lenticular plateau levels (~400
nmol/g wet weight) at 0.5% and 2.0% but levels remained three times higher at 5 h at 2% versus 0.5% concentration,
respectively. In vitro studies showed a 100 fold higher L-arginine level than NAC levels, implicating high affinity uptake
of the former.
Conclusions:  L-Arginine  when  applied  both  orally  and  topically  is  a  potent  and  broad  suppressor  of  advanced
ascorbylation in the lens. Its uptake in rabbit lens upon topical application suggests transcorneal uptake into the human
lens should be feasible for testing its potential anticataract properties in clinical trials.
Aging  human  lens  crystallins  accumulate  several
modifications  which  include  the  formation  of  protein
disulfides,  oxidation  of  methionine  residues,  protein
fragmentation  and  cross-linking  by  disulfide  and  non-
disulfide bonds, deamination, deamidation and accumulation
of  colored  and  colorless,  fluorescent  or  non-fluorescent
products [1]. The significance of these modifications is that
they can destabilize lens crystallins, impair their chaperone
function, unfold the protein, and increase their susceptibility
toward oxidation and aggregation, eventually leading to the
formation of high molecular weight products that are opaque,
i.e., cataractous.
Among these modifications, our laboratory has obtained
strong evidence for the hypothesis that ascorbic acid oxidation
products  are  responsible  for  the  formation  of  crystallin
adducts  and  cross-links  in  vivo  [2].  In  this  process,
dehydroascorbic acid (DHA) and its degradation products 2,3-
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diketogulonic acid (DKG), xylosone, and erythrulose can act
as precursors of the lysine-arginine crosslink pentosidine, the
lysine-lysine cross-links vesperlysine A and K2P, the arginine
hydroimidazolone  of  glyoxal  (G-H1)  and  methylglyoxal
(MG-H1),  and  the  lysine  adducts  carboxymethyl-  and
carboxyethyl-lysine (CML, CEL). Examples are shown in
Figure 1. All these modifications are present in the aging
human lens [3] and could be duplicated in the transgenic mice
that expresses the human vitamin C transporter 2 (hSVCT2)
in their lens [2] and in vitro [4,5]. In these mice the ascorbate
levels are as high as those present in the human lens, i.e., 1–
3 mM.
While there is ample in vitro evidence for the fact that
crystallin ascorbylation and glycation can be deleterious on
the lens crystallin structure and function [6-8], the critical
questions  are  1)  whether  these  can  be  pharmacologically
prevented, and 2) whether prevention of the latter delays the
progression of age-related nuclear sclerosis. Toward the first
question,  we  have  previously  tested  the  ability  of  several
orally administered candidate pharmacological compounds to
block  ascorbylation  in  the  hSVCT2  mouse  lens,  i.e.,  the
guanidino  compounds  NC-1  (L-arginine)  and  NC-2  (γ-
guanidinobutyric  acid),  aminoguanidine,  the  sulfhydryl
compound  penicillamine,  and  the  nucleophilic  scavenger
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2221pyridoxamine.  The  compound  with  the  most  consistent
activity was NC-1, i.e., L-arginine fed at the concentration of
0.1%  (wt/wt)  in  food  [9].  All  tested  modifications  were
decreased by 25%–65%.
As a preamble to a clinical trial, we now have investigated
whether topical application for seven months of L-arginine,
γ-guanidinobutyric acid, N-acetylcysteine, and penicillamine
(a copper chelator) to one eye of hSVCT2 mice can block
crystallin ascorbylation compared to the control eye. This
demonstration is essential since the most desirable clinical
outcome  would  be  to  demonstrate  that  age-related
modifications  and  nuclear  sclerosis  can  be  delayed  using
topical instead of systemic application. We have also tested
whether L-arginine can also be taken up into the rabbit lens in
vitro as well as when applied topically to the eye.
METHODS
Experimental  animals:  All  animal  experiments  were
conducted in accordance with procedures approved by the
Case Western Reserve University, Cleveland, OH Animal
Care Committee and conformed to the ARVO Statement for
use of Animals in Ophthalmic and Vision Research. Animals
Figure 1. Structure of AGEs identified in the aging human lens.
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2222were housed under diurnal lighting condition and allowed free
access  to  food  and  water.  hSVCT2  transgenic  mice  were
maintained  as  described  previously  [2].  The  genetic
background  of  these  transgenic  mice  is  C57BL/6  after
multiple rounds of breeding with this strain.
Eye  drop  formulation  and  topical  application  to  hSVCT2
mouse eye: L-Arginine (A5131), DL-penicillamine (P5125),
γ-guanidinobutyric  acid  (G6503),  and  N-acetyl-L-cysteine
(N7250) were all purchased from Sigma Company (St. Louis,
MO). Solutions containing 0.1% of inhibitor were produced
in phosphate buffer saline (PBS) whereby the pH was adjusted
to  7.4  as  needed  and  sterilized  over  0.2  µm  filters.  The
solutions were aliquoted into 1 ml fractions and stored in a
−80 °C freezer. hSVCT2 transgenic mice (n=10) received
twice per day, 5 days per week starting at 2 months and
continued till 9 months of age, one eye drop of inhibitor in the
Figure 2. Levels of protein-bound fluorescence in transgenic mouse
lens protein with and without inhibitor treatment. A: Fluorescence at
λex/em 335/385 nm and B: Fluorescence at λex/em 370/440 nm. One-
way  ANOVA  was  used  followed  by  post-hoc  analysis  for  all
comparisons  (n=10  per  group).  L-Arginine  (ARG)  significantly
reduced fluorescence at 335/385 nm (p<0.001) and 370/440 nm
(p<0.001).  N-acetylcysteine  (NAC)  significantly  reduced  the
fluorescence at 335/385 nm (p<0.001). GBA=guanidinobutyric acid,
PA=penicillamine.
right  eye  and  vehicle  control  in  the  left  eye.  Mice  were
sacrificed and eyes were removed and decapsulated to release
the lenses. These were processed for advanced glycation end
product (AGE) determination as described below.
Rabbit lens topical inhibitors kinetic study: Two rabbits in
each group received one drop of a solution of 0.5% inhibitor
dissolved in Systane Lubricant Eye Drops (Alcon, Fort Worth,
TX) on the right eye and 2% inhibitor similarly prepared on
the left eye. The rabbits were sacrificed at various time points
and the lenses were quickly dissected and washed three times
with ice-cold PBS. The lenses were then homogenized in
1.0 ml ice-cold PBS, centrifuged at 20,000× g for 25 min and
the supernatant was used to determine the content of inhibitors
using liquid chromatography/mass spectrometry (LC/MS).
In vitro incubation of rabbit lenses with L-arginine and N-
acetylcysteine:  Freshly  excised  rabbit  lenses  were
preincubated for 8 h in Dulbecco’s modified Eagle’s medium
(Medium  199;  Sigma  Company)  to  verify  viability,  and
further incubated with or without added 10 mM L-arginine or
N-acetylcysteine in the presence of 25 mM glucose, or 5 mM
ascorbate, or 100 µM dehydroascorbate. After 24 h, lenses
were processed to determine the uptake of L-arginine or N-
acetylcysteine (NAC).
Processing of mice lenses for the determination of protein-
bound  AGEs:  Lenses  were  homogenized  in  ice-cold  10%
trichloracetic acid (TCA), and placed on ice for 15 min. The
TCA protein precipitate was washed twice with 500 μl of ethyl
ether  and  further  delipidated  with  500  μl  of  chloroform/
methanol (2:1) at 4 °C overnight, then soaked in water and
lyophilized. The lyophilized sample representing on average
1 mg protein was reconstituted with 500 μl of 5.0 mM argon-
exchanged,  Chelex-treated  phosphate  buffer  (pH  7.0)  by
sonication. The suspension was solubilized with 35 µl of
10 mg/ml protease K at 37 °C for 24 h for determination of
protein-bound fluorescence. The sample was then divided into
two equal fractions, one of which was subjected to further
enzymatic digestion, and the other subjected to hydrolysis
with 6 N HCl following our previous described method [2] to
release free AGEs.
Fluorescence  spectroscopy  and  advanced  glycation
endproducts  determination:  The  fluorescence  at  λex/em
370/440 nm and 335/385 nm of the enzymatic lens protein
digest was measured with a spectrofluorometer (821-F; Jasco,
Easton, MD). The data was expressed as fluorescence units
per  unit  protein  measured  as  leucine  equivalent.
Carboxymethyl-lysine  (CML)  and  carboxyethyl-lysine
(CEL)  were  determined  by  the  gas  chromatography/mass
spectrometry (GC/MS) method and the hydroimidazolones G-
H1 and MG-H1, and glucosepane were determined by the LC/
MS method as described in our previous study [10].
Determination of L-arginine and N-acetylcysteine: Uptake of
L-arginine  and  N-acetylcysteine  was  determined  in  the
protein-free rabbit lens extract using the same method as for
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2223the rabbit lens topical inhibitor study (see above). Arginine
was assayed by isotope dilution technique using 15N-arginine
as an internal standard. The m/z transition 174.9>70.1 and
176.9>70.2  were  used  for  arginine  and  15N-arginine,
respectively. Cone voltage (Cv) and collision energies (Ce)
were  60  V/22  eV  and  60  V/20  eV,  respectively.  N-
acetylcysteine was quantified based on the peak area for the
transition m/z 163.66x>121.85 (loss of acetyl; Cv:48 V, CE:
9 eV, respectively) in the same chromatographic analysis run
as for L-arginine.
Statistical analysis: All values were expressed as means±SD.
Statistical significance of the differences in mean values was
assessed by repeated-measures of ANOVA or Student’s t-test.
P values of <0.05 were considered statistically significant.
RESULTS
One  drop  of  potential  inhibitors,  each  0.1%  dissolved  in
phosphate buffer saline of L-arginine, guanidinobutyric acid,
DL-penicillamine, or N-acetylcysteine was applied five days
a week to the right eye of hSVCT2 mice. The contralateral eye
received vehicle only, i.e., PBS. Total lens crystallins were
isolated,  enzymatically  digested,  and  processed  for  the
measurement of protein-bound fluorescence at 335/385 nm
and  370/440  nm  and  advanced  glycation/ascorbylation
products as previously described [10]. After seven months, L-
arginine suppressed pentosidine-like fluorescence at 335/385
nm and 370/440 nm fluorescence by 40% (p<0.001; Figure
2). Interestingly, the latter was also 50% suppressed by N-
acetylcysteine (p<0.05; Figure 2). NAC suppressed 335/385
fluorescence,  though  not  significantly.  L-Arginine  also
suppressed CML, CEL, and glucosepane cross-links by 35%
(p<0.05),  30%  (p<0.05)  and  37%  (p<0.05),  respectively
(Figure  3A,B,E).  Surprisingly  it  did  not  suppress  the
methylglyoxal  hydroimidazolone  MG-H1  and  the  glyoxal
hydroimidazolone  G-H1  (Figure  2C,D).  Except  for  the
positive effect of NAC on 335/385 nm fluorescence (Figure
2A),  neither  the  latter  nor  penicillamine  (PA)  or
guanidinobutyric acid (NAC-2) had any effect on any of the
advanced glycation endproducts (Figure 2 and Figure 3).
The above findings suggest that mice have the ability to
take up L-arginine and N-acetylcysteine trans-corneally. To
find out if this was potentially applicable to other species, we
determined the uptake in vitro and in vivo of L-arginine in
rabbit  lenses  upon  transcorneal  application.  Lenses  were
Figure  3.  Additional  AGE  levels  in
mouse lens with or without inhibitor eye
drop treatment. A: Mouse lens protein
CML levels were significantly reduced
by L-arginine (p<0.05). B: Mouse lens
protein  CEL  levels  were  significantly
reduced  by  L-arginine  (p<0.05).  C:
Mouse  lens  protein  GH1  were  not
affected by inhibitors (p=N.S.) versus
vehicle control. D: Mouse lens protein
MG-H1  levels  were  not  affected  by
inhibitors  (p=N.S)  versus  vehicle
control.  E:  Mouse  lens  protein
glucosepane  levels  were  significantly
reduced by L-arginine (p<0.05). One-
way  ANOVA  was  used  followed  by
post-hoc  analysis  for  all  comparisons
(n=10 per group). For abbreviations, see
Figure 1.
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2224incubated with 5 mM concentration of L-arginine in ascorbic
acid,  dehydroascorbic  acid  (DHA)  or  D-glucose  in
Dulbecco’s modified Eagle’s medium 199 for 24 h under
different conditions to simulate either the ascorbate or glucose
concentration of the medium. The chosen concentration (i.e.,
5 mM L-arginine) was five times lower than that applied to
the hSVCT2 mouse eye. i.e., 0.5% or 28 mM. The results were
compared  with  5  mM  N-acetylcysteine  (NAC)  incubated
under similar conditions. As shown in Figure 4, lenticular
arginine levels in the absence of added L-arginine varied from
150 to 210 nmol/g wet weight (mean±SD: 166.5±17.5 nmol/
g wet weight, n=6) and jumped  to values ranging from 780
to  1,432  nmol/g (mean±SD  1,008.7±233.5  nmol/g)   when
lenses were incubated with 5 mM arginine. This increase was
highly significant (p<0.0001).  For comparison, NAC  levels
were  1.60±0.85  nmol/g wet weight (n=4)  in  the presence of 
5  mM   added  NAC,  while  no  NAC  was  detected  in   lenses
incubated without added NAC.
Figure 4. Comparative uptake of L-arginine and N-acetyl-L-cysteine
in rabbit lenses (n=2) incubated with 5 mM L-arginine and 5 mM
NAC with and without presence of 25 mM D-glucose or 5 mM
ascorbic acid and 0.1 mM dehydroascorbic acid for 4 h. The lenses
were washed with cold PBS and homogenized in water for L-arginine
and NAC determination in supernatant by LC/MS.
Finally,  lenticular  uptake  of  L-arginine  upon  in  vivo
transcorneal  application  to  the  rabbit  eye  showed  a  rapid
transcorneal uptake which reached similar lenticular plateau
levels  varying  from  400  to  500  nmol/g  after  120  min,
regardless of whether 0.5 or 2.0% eye drops were applied
(Figure 5). However the latter concentration remained more
elevated  at  4  h  in  presence  of  2.0%  compared  to  0.5%.
Similarly, NAC levels reached a plateau at 2 h, but levels were
three to four times higher and persisted longer with 2.0%
instead of 0.5% NAC.
DISCUSSION
The  above  results  confirm  the  ability  of  L-arginine
(previously  referred  to  as  “NC-1”  [10])  to  suppress  the
formation  of  advanced  ascorbylation  end  products  in  the
hSVCT2 mouse model of human lens brunescence. Quite
remarkably,  except  for  the  fact  that  NAC  lowered  the
fluorescence  at  335/385  nm,  L-arginine  was  the  only
compound able to significantly delay the accumulation of
multiple AGEs.
We tentatively attribute the ability of arginine to suppress
AGE formation to its ability to scavenge oxoaldehydes such
as  glyoxal  and  methylglyoxal,  as  well  as  DHA  and  its
degradation  products  xylosone,  erythrulose,  and
deoxythreosone.  While  γ-guanidinobutyric  acid  had
expectedly similar effects when fed orally to hSVCT2 mice,
no such effects were noted in the present experiments. We
attribute this discrepancy to the fact that specific transporters
for L-arginine must be present in the cornea and lens, which
preferentially favor its uptake over γ-guanidinobutyric acid
into the lens. When orally fed at 0.1% in the diet, presumably
sufficient concentrations of the latter are achieved to allow
scavenging of oxoaldehydes. Indeed Jain-Vakkalagadda et al.
[10] found that transport of L-arginine across rabbit cornea
was saturable (Km=306±72 μM and Vmax=0.12±0.01 nmol min
−1cm−2) and was Na+, Cl-, and energy dependent, and inhibited
by  neutral  and  cationic  amino  acids.  The  specific  B(0,+)
arginine transporter was identified in both rabbit and human
corneas.
Concerning the uptake of arginine into the lens, numerous
studies on the uptake of various amino acids into the animal
and human lens have been done in the past [11-14]. One study
suggests a ~1:1 ratio of lens: aqueous arginine levels [11],
which would exclude the presence of high affinity uptake into
the  lens.  However  the  aqueous:  plasma  ratio  was  ~3:1
implying active uptake from the plasma into the aqueous.
Systematic  studies  on  arginine  transport  are  lacking  and
molecular studies are needed to clarify this field.
L-Arginine is an attractive drug for the potential delay of
senile cataracts for multiple reasons. First, recent studies from
our laboratory have unequivocally demonstrated that arginine
is the single major damaged crystallin residue by advanced
glycation during aging [3]. In addition, various studies by
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2225others have demonstrated the ability of arginine to block in
vitro and in vivo advanced glycation [15-22]. Second, recent
studies also suggest that arginine added to proteins in solution
has stabilizing effects by the prevention of aggregation and
improving  solubilization  [23,24].  Thus,  topically  applied
arginine might improve the progression of cataractogenesis
by acting as an AGE inhibitor and a protein stabilizing agent.
Finally and importantly, L-arginine has low toxicity since it
is a natural constituent.
Another  important  aspect  of  the  above  study  is  the
demonstration that N-acetylcysteine was able to block protein
bound formation of AGE fluorescence. The latter might be a
consequence of UV or other oxidation mediated damage to
tryptophan residues, rather than a glycation-related process
[25]. NAC is widely used for suppression of oxidant stress in
cell culture experiments, and is an approved clinical drug of
low toxicity for the treatment of acetaminophen poisoning and
various other conditions [26].
In  summary,  the  above  study  confirms  the  in  vivo
potential of L-arginine as a blocking agent of carbonyl stress
in the lens. In addition, our finding that topical application of
NAC was potent at decreasing protein-bound fluorescence at
335/385 nm, and to some extent at 370/440 nm, suggests it
might be useful as an adjuvant to L-arginine for combating
combined carbonyl and oxidant stress in the pathogenesis of
age-related nuclear cataracts.
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